A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies

Autor: Chia-Chi Lin, Elena Garralda, Patrick Schöffski, David S. Hong, Lillian L. Siu, Miguel Martin, Michela Maur, Rina Hui, Ross A Soo, Joanne Chiu, Tian Zhang, Brigette Ma, Chrisann Kyi, Daniel SW Tan, Philippe A. Cassier, John Sarantopoulos, Andrew Weickhardt, Richard D. Carvajal, Jennifer Spratlin, Taito Esaki, Fréderic Rolland, Wallace Akerley, Barbara Deschler-Baier, Lawrence Rispoli, Tanay S. Samant, Niladri Roy Chowdhury, Daniel Gusenleitner, Eunice L. Kwak, Vasileios Askoxylakis, Filippo De Braud

Publikováno v: OncoImmunology, Vol 13, Iss 1 (2024)

Ieramilimab, a humanized anti-LAG-3 monoclonal antibody, was well tolerated in combination with the anti-PD-1 antibody spartalizumab in a phase 1 study. This phase 2 study aimed to further investigate the efficacy and safety of combination treatment

Externí odkaz: https://doaj.org/article/fba32163599d40e7abcb0008f2589a1a

A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies.

Autor: Lin CC; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan., Garralda E; Vall d'Hebron Institute of Oncology (VHIO), Vall d´Hebron Hospital, Barcelona, Spain., Schöffski P; Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, KU Leuven, Leuven, Belgium., Hong DS; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, University of Texas and MD Anderson Cancer Center, Houston, TX, USA., Siu LL; Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, Canada., Martin M; Gregorio Marañón Hospital, Universidad Complutense, Madrid, Spain., Maur M; Oncology and Haematology Department, Università degli Studi di Modena e Reggio Emilia, Emilia-Romagna, Italy., Hui R; Department of Medical Oncology, Westmead Hospital and the University of Sydney, Sydney, Australia., Soo RA; Department of Haematology-Oncology, National University Cancer Institute, Singapore., Chiu J; Department of Medicine, Queen Mary Hospital, Hong Kong, China., Zhang T; Department of Medicine, Duke Cancer Institute, Durham, NC, USA., Ma B; Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Hong Kong, China., Kyi C; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Tan DS; National Cancer Centre, Singapore and Duke-NUS Medical School, Singapore., Cassier PA; Department of Medical Oncology, Centre Léon Bérard, Lyon, France., Sarantopoulos J; Institute for Drug Development, Mays Cancer Center at University of Texas Health San Antonio MD Anderson Cancer Center, San Antonio, TX, USA., Weickhardt A; Medical Oncology Dept, Olivia Newton-John Cancer Centre, Austin Health, Melbourne, Victoria, Australia., Carvajal RD; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA., Spratlin J; Cross Cancer Institute, University of Alberta, Edmonton, Canada., Esaki T; Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan., Rolland F; Department of Medical Oncology, Institut de Cancérologie de l'Ouest - Centre René Gauducheau, Nantes, France., Akerley W; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Deschler-Baier B; Translational Oncology, Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany., Rispoli L; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Samant TS; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Chowdhury NR; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Gusenleitner D; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Kwak EL; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Askoxylakis V; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., De Braud F; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy and Oncology and Hemato-oncology Department, University of Milan, Milan, Italy.

Publikováno v: Oncoimmunology [Oncoimmunology] 2023 Dec 20; Vol. 13 (1), pp. 2290787. Date of Electronic Publication: 2023 Dec 20 (Print Publication: 2024).